{"success":true,"data":{"pressRelease":{"id":"149287","rtpr_id":"nPnbSy70ha-20260922","ticker":"BBNX","exchange":"NASDAQ","all_tickers":["BBNX"],"title":"BBNX Class Action: Beta Bionics Investors are Notified of the Upcoming November 3 Deadline in Ongoing Securities Fraud Class Action over Medical Device Safety","author":"PR Newswire","published_at":"2026-09-22T10:35:00.050Z","article_body":"BBNX Class Action: Beta Bionics Investors are Notified of the Upcoming November 3 Deadline in Ongoing Securities Fraud Class Action over Medical Device Safety\nPR Newswire\n\nNEW YORK, Sept. 22, 2026\n\nA securities fraud class action lawsuit has been filed on behalf of Beta\nBionics investors after its stock plummeted over 37% because Beta Bionics\nallegedly misled investors about the safety, efficacy, and commercial success\nof its iLet medical device, potentially violating the federal securities laws.\n\nNEW YORK, Sept. 22, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar\nFonti & Auld LLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4779220-1&h=354340185&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit&a=Bleichmar+Fonti+%26+Auld+LLP)\n announces that a class action lawsuit has been filed against Beta Bionics,\nInc. (NASDAQ: BBNX) and certain of the company's senior executives for\nsecurities fraud after its significant stock drop resulting from potential\nviolations of the federal securities laws.\n\nIf you invested in Beta Bionics, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4779220-1&h=495875388&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit)\n.\n\nKey Details of the Beta Bionics ($BBNX) Class Action:\n\n * Lead Plaintiff Deadline: November 3, 2026\n * Alleged Misconduct: Securities fraud alleging that Beta Bionics misled\ninvestors about the safety of its iLet medical device\n * Largest Alleged Stock Drop: January 8–9, 2026 – 37% Stock Drop\n * Court: U.S. District Court for the Central District of California\n * Action: Contact\nBFA Law\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4779220-1&h=3968531261&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit&a=BFA+Law)\n\n to discuss your rights\nInvestors have until November 3, 2026 to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nBeta Bionics common stock. The class action is pending in the U.S. District\nCourt for the Central District of California. It is captioned Holtzman v.\nBeta Bionics, Inc., No. 26-cv-9999.\n\nWhy is Beta Bionics Being Sued for Securities Fraud?\n\nBeta Bionics is a commercial-stage medical device company that offers an\nautomated insulin delivery system for the treatment of diabetes, known as the\niLet Bionic Pancreas insulin pump (\"iLet\"), launched in 2023. The iLet is an\ninsulin delivery system for treatment of diabetes types 1 and 2 that purports\nto be fully autonomous, determining 100% of insulin doses without manual\ncarbohydrate counting or correction calculations by the user.\n\nThe complaint alleges that Beta Bionics falsely touted \"the superior clinical\noutcomes of the iLet\" and that healthcare professionals \"are seeing good\nresults from their patients and becoming more comfortable prescribing the\niLet.\"\n\nHowever, the complaint alleges that in June 2025, the FDA issued Beta Bionics\na Form 483 detailing more than 18,000 unreported complaints from iLet users\nsince its launch. The complaints concerned, allegedly, cases of\nlife-threatening hypoglycemia due to iLet's aggressive insulin dosing\nalgorithm which Beta Biotics failed to investigate or take corrective actions\nto address.\n\nWhy did Beta Bionics' Stock Drop?\n\nOn January 8, 2026, after hours, Beta Bionics announced that a key business\nmetric—the number of new patients starting iLet treatment, or \"new patient\nstarts\"—had missed analyst estimates by nearly 10%. As alleged, this news\ncaused the price of Beta Bionics stock to decline by $11.85 per share, or 37%,\nfrom a closing price of $31.99 per share on January 8, 2026 to a closing price\nof $20.14 per share on January 9, 2026.\n\nThen, on February 24, 2026, the FDA publicly released a 10-page warning\nletter, which it had previously sent to Beta Bionics, stating that the Company\nfailed to report instances of hypoglycemia caused by iLet malfunctions. As\nalleged, this news caused the price of Beta Bionics stock to decline by $0.66,\nor 4.9%, from a closing price of $13.55 per share on February 24, 2026 to a\nclosing price of $12.89 per share on February 25, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4779220-1&h=495875388&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit)\n\nWhat Can You Do?\n\nIf you invested in Beta Bionics, you may have legal options and are encouraged\nto submit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4779220-1&h=495875388&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit)\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named \"Elite Trial Lawyers\" by the National Law Journal, \"Litigation\nStars\" by Benchmark Litigation, among the top \"500 Leading Plaintiff\nFinancial Lawyers\" by Lawdragon, \"Titans of the Plaintiffs' Bar\" by Law360,\nand \"SuperLawyers\" by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff's securities litigation law firm, with clients\nnoting: \"[t]here is no better service provider in the practice area,\" \"[t]he\ninterest of the client is always front and center,\" and \"[t]here isn't a\nbetter firm in this space.\" One testimonial described the firm as \"nimble and\nentrepreneurial,\" with a \"relentless focus on adding value for clients.\"\n\nBFA's notable successes include a recovery of over $900 million in value from\nTesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4779220-1&h=1221653185&u=https%3A%2F%2Fwww.bfalaw.com%2F&a=https%3A%2F%2Fwww.bfalaw.com)\n.\n\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4779220-1&h=495875388&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit)\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/bbnx-class-action-beta-bionics-investors-are-notified-of-the-upcoming-november-3-deadline-in-ongoing-securities-fraud-class-action-over-medical-device-safety-302885395.html\n(https://www.prnewswire.com/news-releases/bbnx-class-action-beta-bionics-investors-are-notified-of-the-upcoming-november-3-deadline-in-ongoing-securities-fraud-class-action-over-medical-device-safety-302885395.html)\n\nSOURCE Bleichmar Fonti & Auld LLP\n\n\n\nAdam McCall, adam@bfalaw.com, 212.789.3619\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1804470/Bleichmar-Fonti-Auld-LLP-Logo.jpg?id=OA2961393\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnbSy70ha-20260922","title":"BBNX Class Action: Beta Bionics Investors are Notified of the Upcoming November 3 Deadline in Ongoing Securities Fraud Class Action over Medical Device Safety","author":"PR Newswire","ticker":"BBNX","created":"2026-09-22T10:35:00.050Z","tickers":["BBNX"],"exchange":"NASDAQ","article_body":"BBNX Class Action: Beta Bionics Investors are Notified of the Upcoming November 3 Deadline in Ongoing Securities Fraud Class Action over Medical Device Safety\nPR Newswire\n\nNEW YORK, Sept. 22, 2026\n\nA securities fraud class action lawsuit has been filed on behalf of Beta\nBionics investors after its stock plummeted over 37% because Beta Bionics\nallegedly misled investors about the safety, efficacy, and commercial success\nof its iLet medical device, potentially violating the federal securities laws.\n\nNEW YORK, Sept. 22, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar\nFonti & Auld LLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4779220-1&h=354340185&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit&a=Bleichmar+Fonti+%26+Auld+LLP)\n announces that a class action lawsuit has been filed against Beta Bionics,\nInc. (NASDAQ: BBNX) and certain of the company's senior executives for\nsecurities fraud after its significant stock drop resulting from potential\nviolations of the federal securities laws.\n\nIf you invested in Beta Bionics, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4779220-1&h=495875388&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit)\n.\n\nKey Details of the Beta Bionics ($BBNX) Class Action:\n\n * Lead Plaintiff Deadline: November 3, 2026\n * Alleged Misconduct: Securities fraud alleging that Beta Bionics misled\ninvestors about the safety of its iLet medical device\n * Largest Alleged Stock Drop: January 8–9, 2026 – 37% Stock Drop\n * Court: U.S. District Court for the Central District of California\n * Action: Contact\nBFA Law\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4779220-1&h=3968531261&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit&a=BFA+Law)\n\n to discuss your rights\nInvestors have until November 3, 2026 to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nBeta Bionics common stock. The class action is pending in the U.S. District\nCourt for the Central District of California. It is captioned Holtzman v.\nBeta Bionics, Inc., No. 26-cv-9999.\n\nWhy is Beta Bionics Being Sued for Securities Fraud?\n\nBeta Bionics is a commercial-stage medical device company that offers an\nautomated insulin delivery system for the treatment of diabetes, known as the\niLet Bionic Pancreas insulin pump (\"iLet\"), launched in 2023. The iLet is an\ninsulin delivery system for treatment of diabetes types 1 and 2 that purports\nto be fully autonomous, determining 100% of insulin doses without manual\ncarbohydrate counting or correction calculations by the user.\n\nThe complaint alleges that Beta Bionics falsely touted \"the superior clinical\noutcomes of the iLet\" and that healthcare professionals \"are seeing good\nresults from their patients and becoming more comfortable prescribing the\niLet.\"\n\nHowever, the complaint alleges that in June 2025, the FDA issued Beta Bionics\na Form 483 detailing more than 18,000 unreported complaints from iLet users\nsince its launch. The complaints concerned, allegedly, cases of\nlife-threatening hypoglycemia due to iLet's aggressive insulin dosing\nalgorithm which Beta Biotics failed to investigate or take corrective actions\nto address.\n\nWhy did Beta Bionics' Stock Drop?\n\nOn January 8, 2026, after hours, Beta Bionics announced that a key business\nmetric—the number of new patients starting iLet treatment, or \"new patient\nstarts\"—had missed analyst estimates by nearly 10%. As alleged, this news\ncaused the price of Beta Bionics stock to decline by $11.85 per share, or 37%,\nfrom a closing price of $31.99 per share on January 8, 2026 to a closing price\nof $20.14 per share on January 9, 2026.\n\nThen, on February 24, 2026, the FDA publicly released a 10-page warning\nletter, which it had previously sent to Beta Bionics, stating that the Company\nfailed to report instances of hypoglycemia caused by iLet malfunctions. As\nalleged, this news caused the price of Beta Bionics stock to decline by $0.66,\nor 4.9%, from a closing price of $13.55 per share on February 24, 2026 to a\nclosing price of $12.89 per share on February 25, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4779220-1&h=495875388&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit)\n\nWhat Can You Do?\n\nIf you invested in Beta Bionics, you may have legal options and are encouraged\nto submit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4779220-1&h=495875388&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit)\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named \"Elite Trial Lawyers\" by the National Law Journal, \"Litigation\nStars\" by Benchmark Litigation, among the top \"500 Leading Plaintiff\nFinancial Lawyers\" by Lawdragon, \"Titans of the Plaintiffs' Bar\" by Law360,\nand \"SuperLawyers\" by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff's securities litigation law firm, with clients\nnoting: \"[t]here is no better service provider in the practice area,\" \"[t]he\ninterest of the client is always front and center,\" and \"[t]here isn't a\nbetter firm in this space.\" One testimonial described the firm as \"nimble and\nentrepreneurial,\" with a \"relentless focus on adding value for clients.\"\n\nBFA's notable successes include a recovery of over $900 million in value from\nTesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4779220-1&h=1221653185&u=https%3A%2F%2Fwww.bfalaw.com%2F&a=https%3A%2F%2Fwww.bfalaw.com)\n.\n\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4779220-1&h=495875388&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fbeta-bionics-class-action-lawsuit)\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/bbnx-class-action-beta-bionics-investors-are-notified-of-the-upcoming-november-3-deadline-in-ongoing-securities-fraud-class-action-over-medical-device-safety-302885395.html\n(https://www.prnewswire.com/news-releases/bbnx-class-action-beta-bionics-investors-are-notified-of-the-upcoming-november-3-deadline-in-ongoing-securities-fraud-class-action-over-medical-device-safety-302885395.html)\n\nSOURCE Bleichmar Fonti & Auld LLP\n\n\n\nAdam McCall, adam@bfalaw.com, 212.789.3619\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1804470/Bleichmar-Fonti-Auld-LLP-Logo.jpg?id=OA2961393\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-22T10:35:00.096855769Z","server_sent_at_ms":1790073300096},"received_at":"2026-09-22T10:35:00.156Z","source_url":"https://www.prnewswire.com/news-releases/bbnx-class-action-beta-bionics-investors-are-notified-of-the-upcoming-november-3-deadline-in-ongoing-securities-fraud-class-action-over-medical-device-safety-302885395.html"},"analysis":{"id":"138008","press_release_id":"149287","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["Securities fraud class action pending against BBNX; lead plaintiff deadline November 3, 2026","FDA warning letter citing failure to report iLet hypoglycemia malfunctions","Alleged more than 18,000 unreported device complaints since iLet launch","New patient starts missed analyst estimates by nearly 10%, triggering a 37% one-day stock drop in January 2026"],"eventType":"legal_litigation","narrative":"Plaintiff firm Bleichmar Fonti & Auld LLP announced that a securities fraud class action has been filed against Beta Bionics and certain senior executives, with a November 3, 2026 deadline for investors to seek lead plaintiff appointment.\n\nThe suit, pending in the U.S. District Court for the Central District of California under Sections 10(b) and 20(a) of the Exchange Act, alleges Beta Bionics misled investors about the safety of its iLet insulin delivery device, citing an FDA Form 483 detailing more than 18,000 unreported user complaints and a subsequent FDA warning letter over unreported hypoglycemia malfunctions.\n\nThe complaint points to a 37% one-day stock drop on January 9, 2026 after new patient starts missed analyst estimates by nearly 10%, and a further 4.9% decline after the warning letter was publicly released in February 2026.\n\nThis release is a law-firm solicitation on contingency rather than an issuer disclosure; no class has been certified and no settlement is in place, so treat it as low-signal noise despite the underlying regulatory allegations.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation — suppress; monitor for issuer-sourced 8-K or FDA developments instead."},"keyFigures":{"customDimensions":{"lead_plaintiff_deadline":"November 3, 2026","closing_price_jan_8_2026":31.99,"closing_price_jan_9_2026":20.14,"closing_price_feb_24_2026":13.55,"closing_price_feb_25_2026":12.89,"stock_drop_percent_feb_2026":"4.9%","stock_drop_percent_jan_2026":"37%","stock_price_decline_feb_2026":0.66,"stock_price_decline_jan_2026":11.85,"alleged_unreported_device_complaints":"more than 18,000","new_patient_starts_miss_vs_estimates":"nearly 10%"}},"quotedText":"","namedEntities":{"people":[{"name":"Adam McCall","role":"BFA Law media contact"},{"name":"Holtzman","role":"named plaintiff in the class action"}],"products":["iLet","iLet Bionic Pancreas insulin pump"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"class action defendant / filer"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm / release author"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"},{"name":"Tesla, Inc.","relationship":"mentioned — prior BFA litigation recovery"},{"name":"Teva Pharmaceutical Ind. Ltd.","relationship":"mentioned — prior BFA litigation recovery"}],"dollarAmounts":[{"amount":"$11.85 per share","context":"alleged stock price decline Jan 8-9, 2026"},{"amount":"$31.99 per share","context":"BBNX closing price January 8, 2026"},{"amount":"$20.14 per share","context":"BBNX closing price January 9, 2026"},{"amount":"$0.66","context":"alleged stock price decline Feb 24-25, 2026"},{"amount":"$13.55 per share","context":"BBNX closing price February 24, 2026"},{"amount":"$12.89 per share","context":"BBNX closing price February 25, 2026"},{"amount":"over $900 million","context":"prior BFA recovery from Tesla, Inc.'s Board of Directors"},{"amount":"$420 million","context":"prior BFA recovery from Teva Pharmaceutical Ind. Ltd."}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued under the Bleichmar Fonti & Auld LLP wire account, soliciting lead-plaintiff candidates before a November 3, 2026 deadline. No certified class, no settlement, and no new issuer disclosure — the FDA Form 483, warning letter, and January 2026 stock drop are previously reported background."},"tickerRelevance":{"others":[],"primary":"BBNX"},"globalImportance":18,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingEventNote":"References previously disclosed FDA warning letter and January 2026 stock drop; no new issuer disclosure"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Plaintiff firm Bleichmar Fonti & Auld LLP announced that a securities fraud class action has been filed against Beta Bionics and certain senior executives, with a November 3, 2026 deadline for investors to seek lead plaintiff appointment.\n\nThe suit, pending in the U.S. District Court for the Central District of California under Sections 10(b) and 20(a) of the Exchange Act, alleges Beta Bionics misled investors about the safety of its iLet insulin delivery device, citing an FDA Form 483 detailing more than 18,000 unreported user complaints and a subsequent FDA warning letter over unreported hypoglycemia malfunctions.\n\nThe complaint points to a 37% one-day stock drop on January 9, 2026 after new patient starts missed analyst estimates by nearly 10%, and a further 4.9% decline after the warning letter was publicly released in February 2026.\n\nThis release is a law-firm solicitation on contingency rather than an issuer disclosure; no class has been certified and no settlement is in place, so treat it as low-signal noise despite the underlying regulatory allegations.","key_figures":{"customDimensions":{"lead_plaintiff_deadline":"November 3, 2026","closing_price_jan_8_2026":31.99,"closing_price_jan_9_2026":20.14,"closing_price_feb_24_2026":13.55,"closing_price_feb_25_2026":12.89,"stock_drop_percent_feb_2026":"4.9%","stock_drop_percent_jan_2026":"37%","stock_price_decline_feb_2026":0.66,"stock_price_decline_jan_2026":11.85,"alleged_unreported_device_complaints":"more than 18,000","new_patient_starts_miss_vs_estimates":"nearly 10%"}},"named_entities":{"people":[{"name":"Adam McCall","role":"BFA Law media contact"},{"name":"Holtzman","role":"named plaintiff in the class action"}],"products":["iLet","iLet Bionic Pancreas insulin pump"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"class action defendant / filer"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm / release author"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"},{"name":"Tesla, Inc.","relationship":"mentioned — prior BFA litigation recovery"},{"name":"Teva Pharmaceutical Ind. Ltd.","relationship":"mentioned — prior BFA litigation recovery"}],"dollarAmounts":[{"amount":"$11.85 per share","context":"alleged stock price decline Jan 8-9, 2026"},{"amount":"$31.99 per share","context":"BBNX closing price January 8, 2026"},{"amount":"$20.14 per share","context":"BBNX closing price January 9, 2026"},{"amount":"$0.66","context":"alleged stock price decline Feb 24-25, 2026"},{"amount":"$13.55 per share","context":"BBNX closing price February 24, 2026"},{"amount":"$12.89 per share","context":"BBNX closing price February 25, 2026"},{"amount":"over $900 million","context":"prior BFA recovery from Tesla, Inc.'s Board of Directors"},{"amount":"$420 million","context":"prior BFA recovery from Teva Pharmaceutical Ind. Ltd."}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-22T11:43:30.885Z","global_importance":18,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingEventNote":"References previously disclosed FDA warning letter and January 2026 stock drop; no new issuer disclosure"}},"durationMs":144945,"modelName":"glm-5.3-flash"}}